Navigation Links
New JHM policies tighten rules on industry interactions
Date:4/8/2009

Johns Hopkins Medicine has adopted a new policy that significantly limits interactions with industry while ensuring effective, principled and appropriate partnerships with drug and medical device makers.

Called the Johns Hopkins Medicine Policy on Interaction with Industry, the policy, to take effect July 1, strengthens and clarifies several long-standing policies while adding new restrictions on how Johns Hopkins physicians, scientists, students and staff may interact with industry.

"This policy will help us promote a culture in which Hopkins faculty and other personnel can exercise independent, unbiased judgment in all their activities while interacting with industry in appropriate ways that support our missions of delivering excellent care to patients, and integrity in teaching and research," said Edward D. Miller, dean of the medical faculty and CEO of Johns Hopkins Medicine.

Chief among the new rules are those that prohibit the acceptance of gifts or entertainment - including food - regardless of value, from pharmaceutical and medical device companies. Consulting arrangements that carry personal compensation but no real duties also are prohibited, and - beginning in 2010 - Hopkins will no longer accept free pharmaceutical samples, although in some limited cases, de-identified samples (those without the brand name or manufacturer's name) may be used for patient education.

The new policy restricts access by pharmaceutical representatives to non-patient care areas only, and then, only on the invitation of the physician or other Hopkins staff members. Similar restrictions are levied on medical device industry representatives. Unrestricted gifts to the institution from industry may be accepted under certain carefully spelled out circumstances.

"Industry plays a crucial role in advancing medical research and treatments, and the intent is not to discourage principled partnerships," says Julie Gottlieb, assistant dean and director of the JHM Office of Policy Coordination. "The major reason for developing this policy is to limit the impact of industry marketing influence on faculty and physicians' decision making and by so doing protect patients."

Other areas covered by the new policy include:

  • Continuing Medical Education (CME): The Hopkins Office of CME (OCME) will continue to be the sole provider of programs offering CME credit under the Johns Hopkins name, and all industry-supported CME courses must be managed by the OCME. There will be central review of all non-credit educational events supported by industry to ensure that the programs are consistent with Accreditation Council for Continuing Medical Education (ACCME) standards. Other provisions of the policy require disclosure of the industry sponsor whenever a company supports non-credit educational courses, and an outright ban on industry funding for Hopkins' department meetings, retreats or social events.

  • Participation in industry-sponsored programs: Hopkins employees may not speak at or on behalf of industry-sponsored programs (for example, "speakers bureaus") if the arrangement gives a company the right to dictate the content of a presentation, gives a company final approval over the content, or has a Hopkins faculty member or other employee acting as a company spokesperson. In making presentations for which there is industry payment or support, full disclosure must be made of the support. Employees may consult with industry to provide scientific advice provided payment for the service is at fair market value, the arrangement is detailed in a written agreement and complies with the Johns Hopkins University School of Medicine's policy on conflict of commitment, and the arrangement is reported as required by the relevant Hopkins administrative unit.

  • Acceptable professional practices: Funds for professional travel, industry sponsorship of scholarships and other educational support for trainees will be required to be made at the institutional, not individual, level. The policy reiterates an existing ban on ghost-writing.

  • Purchasing of products and services: Strict conflict of interest rules and disclosures will govern the purchase of equipment, products and services.

"Interactions between academic medical centers and industry are complex and important," say Gottlieb. "We continually review and revise our policies to address the challenging issues of industry influence and conflicts of interest. Our goal is to foster a culture at Johns Hopkins in which professionals exercise independent judgment when making clinical decisions."


'/>"/>

Contact: Gary Stephenson
gstephenson@jhmi.edu
410-955-5384
Johns Hopkins Medical Institutions
Source:Eurekalert

Related medicine news :

1. Lincoln Financial Group Announces Family Care Reimbursement Benefit Rider on LTD Policies
2. Hazardous Health Plans: Consumer Reports Investigation Finds Serious Gaps in Individual Health Insurance Policies
3. Policies regarding IRB members industry relationships often lacking
4. House Republican Leader Boehner Says CMS Policies on Home Oxygen Therapy Will Potentially Harm Care Available to Medicare Beneficiaries
5. Perceptions of similar language may prevent understanding of sexual harassment policies
6. Calling Policies Unreasonable, 123 Members of Congress Press for Changes in Medicare Home Oxygen Policies for Emergency Care, Supplies and Other Obligations After 36 Months of Service
7. Risk-Management Policies Needed Now in Nanotechnology, Insighter Piece Concludes; FDLI Sponsors Nanotechnology Meeting, Publishes Book on FDA-Regulated Products
8. Following Ceremony with President Obama, UAN President Ann Converso, RN, Commends New Administration on Meeting with Labor Leaders and Reinstating Pro-Worker Policies
9. Facing Large and Uncontrollable Financial Losses on Individual Policies, Blue Cross Blue Shield of Michigan Will Cut Up to 1000 Jobs in 2009, Reduce Spending and Seek Rate Increases on Individual Plans
10. Pets Best Announces New Underwriter for Pet Insurance Policies
11. Lilly Chairman Taurel Says Promise of Personalized Medicine Could be Jeopardized by Short-Sighted Public Policies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Abilene, Texas (PRWEB) , ... February 24, 2017 , ... ... article that focuses on Bible Prophecy concerning this present generation. Yisrayl makes an ... of this current generation. He explains that the Bible details the current times ...
(Date:2/24/2017)... ... February 24, 2017 , ... ... Senior International Elite division on February 12th. Ms. Esparza qualified into this ... elite qualifier competition held in Las Vegas, Nevada. Frida is one of approximately ...
(Date:2/23/2017)... ... February 23, 2017 , ... The Lymphoma Research ... lymphoma research and serving the lymphoma community through a comprehensive series of education ... Country Club in Miami Beach to host its Swirl: Miami Wine Tasting Event ...
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a ... content marketing, social media management, corporate communications, SEO and cause marketing, is opening ... in nearby New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its ...
(Date:2/23/2017)... ... , ... ERT, a global data and technology company that ... leading clinical development service provider, has selected ERT’s Trial Oversight suite as its ... to an array of circumstances including the use of multiple data capture modalities ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... -- Im Rahmen seiner Schlüsselwachstumsstrategie arbeitet die ... chinesischen Provinz Guizhou, 2017 mit dem Angebot von Anreize schaffenden ... Entwicklung einer eingebetteten Hightech-Schlüsselindustrie. Foto - http://mma.prnewswire.com/media/471342/First_CRH__CHina_Railway_High_Speed__Train_Enters_Guian.jpg ... ... ...
(Date:2/23/2017)... 2017 Research and Markets has announced the ... 2016" report to their offering. ... The latest research Fibromyalgia Drugs Price Analysis ... the global Fibromyalgia market. The research answers the following ... for Fibromyalgia and their clinical attributes? How are they positioned in ...
(Date:2/23/2017)... LA JOLLA, Calif. , Feb. 23, 2017 /PRNewswire/ ... biopharmaceutical company leading the discovery and development of innovative ... quarter and full year 2016 financial results on Thursday, ... Regulus will host a conference call and webcast on ... discuss fourth quarter and full year 2016 financial results ...
Breaking Medicine Technology: